29
Participants
Start Date
May 11, 2010
Primary Completion Date
January 20, 2016
Study Completion Date
January 20, 2016
Thalidomide+Melphalan +Bortezomib+stem cell transplant
Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Hackensack Meridian Health
OTHER